Abstract:T cell immunoglobulin and ITIM domain (TIGIT) is a recently identified T cell coinhibitory receptor. Studies have shown that TIGIT is expressed in colon adenocarcinoma, uterine corpus endometrioid carcinoma, breast carcinoma and kidney renal clear cell carcinoma. However, the role of the TIGIT/human poliovirus receptor (CD155) pathway in the pathogenesis of hepatocellular carcinoma (HCC) remains to be elucidated. In the present study, the expression of TIGIT and CD155 in HCC tissues and peripheral blood were determined, and correlations among TIGIT, CD155, TIGIT(+) CD4(+) T cells, TIGIT(+) regulatory T (Treg) cells and alpha-fetoprotein (AFP) were investigated in order to identify a potential target for diagnosing and treating HCC. Immunohistochemistry, reverse transcription-quantitative PCR analysis and western blotting were used to examine the expression of TIGIT and CD155 in cancerous tissues and peripheral blood collected from patients with HCC. The frequency of TIGIT(+) CD4(+) T cells and TIGIT(+) Treg cells and the concentration of inflammatory cytokines secreted by T cell subsets were analyzed by flow cytometry and a Merck Milliplex assay. Correlations between the frequency of TIGIT(+) CD4(+) T and TIGIT(+) Treg cells and AFP were analyzed using Spearman's rank correlation test. With the degree of cancerous differentiation from high to low, the expression levels of TIGIT and CD155 were upregulated in the cancerous tissues from patients with HCC. TIGIT(+) CD4(+) T cell and TIGIT(+) Treg cell frequencies were decreased in peripheral blood from postoperative patients with HCC. The increased expression of TIGIT was positively correlated with the level of AFP. These results indicate that co-inhibitory receptor TIGIT may be involved in the pathogenesis of HCC and represent a novel target for the diagnosis and treatment of HCC.

Supplementary Figure 1 from Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma

Supplementary Figure 2 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Implication of Myeloid Differentiation Factor 88 Inhibitor TJ-M2010-5 for Therapeutic Intervention of Hepatocellular Carcinoma.

Supplementary Figure 1 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Enhanced Myeloid Differentiation Factor 88 Promotes Tumor Metastasis Via Induction of Epithelial–mesenchymal Transition in Human Hepatocellular Carcinoma

Supplementary Figure 4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Expression of TIGIT/CD155 and Correlations with Clinical Pathological Features in Human Hepatocellular Carcinoma

Supplementary Figure 5 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure 9 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure 6 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure S2 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Figure 4 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figures 5 - 6 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Figure S6 from Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis

Supplementary Figure 3 from E2F8 Contributes to Human Hepatocellular Carcinoma via Regulating Cell Proliferation

Supplementary Figure 7 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation